Akums Drugs and Pharmaceuticals Limited — Updates, 06-02-2025: Press Release

Akums Drugs and Pharmaceuticals has reported robust Q3 performance, with an Adjusted EBITDA growth of 12% YoY, totaling Rs 1,359 million, and a 15% increase in Adjusted PAT to Rs 663 million. The Adjusted EBITDA margin stands at 13.3%, supported by strong profitability in the CDMO segment, despite a decline in total income of 6.1% YoY to Rs 10,250 million. The company successfully contracted a €200 million deal for product manufacture aimed at the European market, marking a significant milestone in their global expansion strategy. The reduction in API losses is notable, even as challenges persist with low prices for cephalosporin APIs. The performance indicates a positive outlook, driven by strong core operations and expanding market reach.